Will Binimetinib be included in medical insurance?

Binimetinib (Binimetinib) is used in combination with encorafenib to treat melanoma (skin cancer) that has spread or cannot be removed by surgery . This method is used only if the melanoma cells have the BRAF V600E or V600K mutation. Bimetinib is also used in combination with encorafenib to treat metastatic non-small cell lung cancer in patients with BRAF V600E mutations. Doctors will use a special test to look for these mutations in tumor samples. Bimetinib belongs to a group of drugs called antineoplastics (cancer drugs), and is available only with a doctor's prescription.

In melanomas with BRAF V600 mutations, there is an abnormal form of BRAF protein that turns on another protein called MEK, which is involved in stimulating cell division. This encourages the development of cancer by allowing uncontrolled cell division. The active substance in bimetinib works by directly blocking MEK and preventing its activation by BRAF, thereby slowing the growth and spread of cancer. In a mouse xenograft model derived from a patient with BRAF V600E mutant NSCLC, the combination of encorafenib and bimetinib resulted in greater antitumor activity in terms of tumor growth inhibition compared with bimetinib alone.

The original drug bimetinib has not yet been launched in China, and therefore is not covered by medical insurance. Bimetiniboriginal drug sold overseas, specifications15mg*84 tablets may cost more than 10,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic drug of Bimetinib produced and launched. For more drug information and specific prices, please consult a medical consultant.